Danisco US Inc.

Hangzhou New Horizon Health Technology Co. Ltd.

Genimmune N.v.

Beijing Percans Oncology Co., Ltd.

Epimmune Inc.

Crown Bioscience, Inc. (taicang)

Cothera Bioscience, Inc.

Yiyou Chen

David Aaron Estell

Scott Douglas Power

Alessandro D Sette

Lilia Maria Babe

Bin Li

Christopher James Murray

Robert W Chesnut

Mark Joseph Newman

Brian D Livingston

Pilar Tijerina

Shuidi Zhong

Yihong Zhang

Lawrence M Deyoung

Manley T F Huang

Jing Li

Anthony G Day

Wang Wei

Henry Qixiang Li

Zhen Yang

Jie Cai

Dan Chen

Jie Yang

Wei Geng

Dagang Guo

Provided are cytokine fusion proteins comprising a first cytokine fused to a second cytokine, for example, interleukin-2 (IL-2) or interferon-β (IFN-β) fused to the N-terminus of tumor necrosis factor-α (TNF-α), and related compositions and methods of use thereof for treating cancers, either as standalone agents or in combination with autologous tumor vaccines and/or immune checkpoint modulatory agents.

Cytokine fusion proteins

Provided are methods of using a MYC gene as a biomarker for predicting therapeutic efficacy of survivin inhibitors such as YM155 monobromide in cancer therapy, and related kits, compositions, and methods for diagnosing and treating cancer in a subject in need thereof.

Biomarkers for cancer therapy

Provided are combination therapies and related compositions and methods for treating cancers, including epithelial tumors, which include a combination of at least two agents such as an epidermal growth factor receptor (EGFR) inhibitor, a mitogen-activated protein kinase (MEK) 1/2 inhibitor; and a cyclin dependent kinase (CDK) 4/6 inhibitor.

Combination therapies for treating cancers

Disclosed is an integrated device for faeces sampling and occult blood detection, which has functions of quantitative collection, dissolution, filtration, detection with immune test strips of the faecal sample, and is convenient to carry and operate, and the device does not leak any liquid during storage, transportation and detection. The device can accurately collect a constant sample with no pollution and leakage, and can quickly determine results of occult blood without the aid of other items. The device can detect faecal occult blood at any time and at any place, can help to overcome the problem of low rate of inspection due to the inconvenience of faeces submission and inspection, further promote the detection of faecal occult blood, and can improve the early diagnosis and screening rate of colorectal cancer of the population.

Integrated device for faeces sampling and occult blood detection

Provided are suspension-based cell culture systems and media for the timely and efficient proliferation of human tumor cell clusters from a patient, and related methods of evaluating the potential responsiveness of the tumor cells and the patient to one or more therapeutic agents.

Tumor cell suspension cultures and related methods

The present invention relates to methods for treating gastric neoplasias, in particular treating patients who have been previously determined to have an EGFR biomarker. Gastric carcinoma (GC) is one of the most common and deadest cancers with &#x2212;1 million diagnoses and &#x2212;0.7 million deaths each year worldwide, with high incidence in Eastern Asia.

Use of EGFR biomarkers for the treatment of gastric cancer with anti-EGFR agents

A selective targeting method is disclosed comprising contacting a library of ligands, particularly a peptide library, with an anti-target to allow the ligands to bind to the anti-target; separating the non-binding ligands from the anti-target bound ligands, contacting the non-binding anti-target ligands with a target allowing the unbound ligands to bind with the target to form a target-bound ligand complex; separating the target-bound ligand complex from ligands which do not bind to the target, and identifying the target-bound ligands on the target-bound ligand complex wherein the target-bound ligands have a Kin the range of about 10to 10M. Additionally claimed are the ligands identified according to the method.

Methods for selective targeting

The invention is drawn to a method of isolating human antibodies.

Isolating human antibodies

The invention relates to the field of biology. In particular, it relates to multi-epitope nucleic acid and peptide vaccines and methods of designing such vaccines to provide increased immunogenicity.

Optimized multi-epitope constructs and uses thereof

Growing community of inventors

San Jose, CA, United States of America

Yiyou Chen